For people 5 to 45 years old trauma is, after HIV/AIDS, the second cause of death. Each year, worldwide, over three million people die as a result of trauma, many after reaching hospital (1). Among trauma patients who do survive long enough to reach hospital, exsanguination is a common cause of death, accounting for nearly half of in-hospital trauma deaths (2). Central nervous system injury and multi-organ failure account for most of the remainder, both of which can be exacerbated by severe bleeding (3).

The haemostatic system helps to maintain the integrity of the circulatory system after severe vascular injury, whether traumatic or surgical in origin (4). Major surgery and trauma trigger similar haemostatic responses and any consequent massive blood loss presents an extreme challenge to the coagulation system. Part of the response to surgery and trauma, in any patient, is stimulation of clot breakdown (fibrinolysis) which may become pathological (hyper-fibrinolysis) in some (4). Antifibrinolytic agents have been shown to reduce blood loss in patients with both normal and exaggerated fibrinolytic responses to surgery and do so without apparently increasing the risk of post-operative complications, most notably there is no increased risk of venous thromboembolism (5).

Systemic antifibrinolytic agents are widely used in major surgery to prevent fibrinolysis and thus reduce surgical blood loss. A recent systematic review (6) of randomized controlled trials of antifibrinolytic agents (mainly aprotinin or tranexamic acid) in elective surgical patients identified 89 trials including 8,580 randomized patients (74 trials in cardiac, eight in orthopedic, four in liver, and three in vascular surgery). The results showed that these treatments reduced the numbers needing transfusion by one third, reduced the volume needed per transfusion by one unit, and halved the need for further surgery to control bleeding. These differences were all highly statistically significant. There was also a statistically non-significant reduction in the risk of death (RR=0.85, 95%CI 0.63 to 1.14) in the antifibrinolytic treated group.

Because the haemostatic abnormalities that occur after injury are similar to those after surgery, it is possible that antifibrinolytic agents might also reduce blood loss, the need for transfusion and mortality following trauma. However, to date there has been only one small randomized controlled trial (70 randomized patients, drug versus placebo: 0 versus 3 deaths) of the effect of antifibrinolytic agents in major trauma (7). As a result, there is insufficient evidence to either support or refute a clinically important treatment effect. Systemic antifibrinolytic agents have been used in the management of eye injuries where there is some evidence that they reduce the rate of secondary hemorrhage (8).

A simple and widely practicable treatment that reduces blood loss following trauma might prevent thousands of premature trauma deaths each year and secondly could reduce exposure to the risks of blood transfusion. Blood is a scarce and expensive resource and major concerns remain about the risk of transfusion-transmitted infection. Trauma is common in parts of the world where the safety of blood transfusion is not assured. A recent study in Uganda estimated the population-attributable fraction of HIV acquisition as a result of blood transfusion to be around 2%, although some estimates are much higher (9,10). Only 43% of the 191 WHO member states test blood for HIV, hepatitis C and B viruses. Every year, unsafe transfusion and injection practices are estimated to account for 8-16 million Hepatitis B
infections, 2.3-4.7 million Hepatitis C infections and 80,000-160,000 HIV infections (11). A large randomized trial is therefore needed of the use of a simple, inexpensive, widely practicable antifibrinolytic treatment such as tranexamic acid (aprotinin is considerably more expensive and is a bovine product with consequent risk of allergic reaction and hypothetically transmission of disease), in a wide range of trauma patients, who when they reach hospital are thought to be at risk of major hemorrhage that could significantly affect their chances of survival.

The CRASH 2 trial will be a large international, placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements (12). The trial aims to recruit some 20,000 patients with trauma and will be one of the largest trauma trials ever conducted. However, it will only be possible to conduct such a trial if hundreds of healthcare professionals worldwide work together to recruit patients to the trial in order to make it a success.

Please contact: CRASH-2 trial Co-ordinating Centre, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7H, Phone +44 0207 958 8128, Fax: +44 0207 299 4663, lan.roberts@lshtm.ac.uk

Tim Coats
University of Leicester
Beverley Hunt
Guy’s and St Thomas’ Trust
Ian Roberts
lan.roberts@lshtm.ac.uk
Haleema Shakur
London School of Hygiene and Tropical Medicine
London, UK

References